Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333906 | 0.81 | LCK (0.43) | CES2MLYCDRORCSMN1; SMN2NR1H3 | |
| SCHEMBL13199238 | 0.81 | MRGPRX4 (0.40) | MLYCDRORCSMN1; SMN2 | |
| SCHEMBL31078115 | 0.79 | MLYCD (0.54) | MLYCDRORCSMN1; SMN2NR1H3NR1H2 | |
| Hydrochloric Acid SCHEMBL15948160 | 0.79 | LCK (0.42) | CES2MLYCDRORCSMN1; SMN2NR1H3 | |
| SCHEMBL14593293 | 0.77 | CES2 (0.45) | CES2MLYCDRORCSMN1; SMN2NR1H3 | |
| SCHEMBL322157 | 0.76 | CES2 (0.67) | CES2 | |
| SCHEMBL8586265 | 0.74 | NR1H2 (0.48) | MLYCDRORCSMN1; SMN2PGRNR1H3 | |
| SCHEMBL38576 | 0.74 | ALDH1A1 (0.40) | CES2 | |
| SCHEMBL271349 | 0.71 | RXRA (0.42) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL18918955 | 0.71 | ALDH1A1 (0.39) | CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809451-B2 | Fluorinated dicarboxylic acid derivative and polymer obtained therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809451-B2 | Fluorinated dicarboxylic acid derivative and polymer obtained therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2395040-A1 | FLUORINATED DICARBOXYLIC ACID DERIVATIVE AND POLYMER OBTAINED THEREFROM | Central Glass Company, Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | MCCC2, AFF2, F13A1 | CES2 2110/4885MLYCD 740/4885RORC 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.